Unveil the power of proteins in biomarker discovery
Locations
Olink User Workshop - Boston | April 30, 2024 | Invite only (Password required to register)
Olink Biomarker Summit – Boston | May 1, 2024
The Olink Biomarker Summit Series is arriving in the number one Biotech hub in the world, Boston, Massachusetts. This event offers you the opportunity to network with other local biomarker researchers who are leading the future of proteomics. Attendees have the exclusive chance to ask questions and engage in-person with key opinion leaders from the area who will be presenting their Olink data.
Venue: Boston Museum of Science
Register for the Boston Summit
Agenda
8:00 a.m. | Registration
8:30 a.m. | Welcome introduction - Carl Raimond, President, Olink Proteomics, Inc.
9:00 a.m. | Quantitative high sensitivity multiplex proteomic platform comparison - Peter Schafer, PhD, Scientific Vice President, Immunology, Cardiovascular, and Neurology Translational Medicine Disease Team, Bristol Myers Squibb
9:35 a.m. | Inflammatory biomarker associations with cognitive function testing, brain MRI phenotypes, incident dementia and Alzheimer’s disease - Peggy Doyle, PhD, Associate Professor of Pathology and Laboratory Medicine; Director, Laboratory for Clinical Biochemistry Research Larner College of Medicine, University of Vermont
10:10 a.m. | Coffee break
10:30 a.m. | High-throughput Proteomics-assisted Biomarker Identification in Neurodegenerative Diseases – Alvis Hu, PhD, Principal Scientist II and Head of Genomic Technologies, Genomics Research Center, AbbVie Inc.
11:05 a.m. | Olink applications in inflammatory skin diseases - Helen He, MD, Dermatology PGY-4 Resident, Icahn School of Medicine at Mount Sinai
11:45 a.m. | Lunch
1:15 p.m. | Olink Insight – an online knowledge and analytics portal for proteomics - Kristin Hellman, MSc, Product Manager, Olink Proteomics, Inc.
1:50 p.m. | Joslin kidney panel of circulating proteins predicting risk of kidney failure as instrument of precision medicine to improve care of diabetic kidney disease - Andrzej Krolewski, MD, PhD, Senior Investigator, Joslin Diabetes Center; Professor of Medicine, Harvard Medical School
2:25 p.m. | Coffee break
2:40 p.m. | Guest Speakers
3:15 p.m. | Keynote speaker – Rob Gerszten, MD, Chief of Cardiology, Beth Israel Deaconess Medical Center
3:50 p.m. | Closing remarks
4:00 p.m. | Coffee reception
Meet some of our speakers
Rob Gerszten, MD
Chief of Cardiology, Beth Israel Deaconess Medical Center
Peter Schafer, PhD
Scientific Vice President, Immunology, Cardiovascular, and Neurology Translational Medicine Disease Team, Bristol Myers Squibb
Peggy Doyle, PhD
Associate Professor of Pathology and Laboratory Medicine; Director, Laboratory for Clinical Biochemistry Research Larner College of Medicine, University of Vermont
Alvis Hu, PhD
Principal Scientist II and Head of Genomic Technologies, Genomics Research Center, AbbVie Inc.
Helen He, MD
Dermatology PGY-4 Resident, Icahn School of Medicine at Mount Sinai
Andrzej Krolewski, MD, PhD
Senior Investigator, Joslin Diabetes Center; Professor of Medicine, Harvard Medical School
Kristin Hellman, MSc
Product Manager, Olink Proteomics, Inc
Carl Raimond
President, Olink Proteomics, Inc.
Olink Biomarker Summit - Montreal | May 7, 2024
The Olink Biomarker Summit Series is coming to Montreal, Canada, offering our Canadian Olink community the opportunity to network with other local biomarker researchers immersed in human disease studies. During the event, attendees will learn and engage local Olink experts and with key-opinion-leaders utilizing Olink technology to make novel discoveries. and local Olink experts. This event promises to be a catalyst for insightful discussions and invaluable connections.
Venue: The PGSS Thomson House
Agenda
9:00 a.m. | Registration & coffee
9:30 a.m. | Welcome introduction to Olink Proteomics – Eric Leblond, Canada Country Manager, Olink Proteomics, Inc.
9:35 a.m. | Enabling proteomics at global scale – Evan Mills, VP, Global Strategic Accounts, Olink Proteomics, Inc.
10:00 a.m. | Olink Proteomics’ PEA technology and workflow overview – Shana Lamers, MS, Field Application Scientist, Olink Proteomics, Inc.
10:30 a.m. | Serum proteomic analyses to advance our understanding of biological and clinical heterogeneity in patients with Ulcerative Colitis and Crohn’s Disease – John Rioux, PhD, Full Professor of Medicine, Montreal Heart Institute; Canada Research Chair in Genetics and Genomic Medicine, Université de Montréal, Canadian Institutes of Health Research
11:15 a.m. | Coffee break
11:30 a.m. | Empowering genomics and biomarker discovery through broad scale proteomics – Cindy Lawley, PhD, Senior Director, Population Health
12:00 p.m. | Discovery a new biomarkers in sickle cell disease – Guillaume Lettre, PhD, Professor of Medicine, Université de Montréal and Montreal Heart Institute; Canada Research Chair in Genetics of Heart and Blood Diseases; Fellow of the College of the Royal Society of Canada
12:30 p.m. | Lunch
1:15 p.m. | Harnessing proteomics for diagnostic and prognostic insights into cancer – Michael Förster, PhD, Scientific Director Oncology, Olink Proteomics, Inc.
1:45 p.m. | Use of Olink PEA technology to identify high value CSF biomarkers in pre-symptomatic elderly subjects with a parental history of Alzheimer’s disease – Judes Poirier, PhD, MD (Hon), K.Q., Deputy Director, McGill University
2:30 p.m. | Multiomics in precision medicine panel discussion – Panel discussion: Moderator – Cindy Lawley, PhD.
3:00 p.m. | Closing remarks – Eric Leblond, Canada Country Manager, Olink Proteomics, Inc.
3:05 p.m. – 4:30 p.m. | Happy hour
Meet some of our speakers
John Rioux, PhD
Full Professor of Medicine, Montreal Heart Institute; Canada Research Chair in Genetics and Genomic Medicine, Université de Montréal, Canadian Institutes of Health Research
Judes Poirier, PhD, MD (Hon), K.Q.
Deputy Director, McGill University
Shana Lamers, MS
Field Application Scientist, Olink Proteomics, Inc.
Evan Mills
Vice President of Americas Sales
Michael Förster, PhD
Scientific Director Oncology, Olink Proteomics, Inc.
Cindy Lawley, PhD
Senior Director, Global Population Health, Olink Proteomics, Inc.
Guillaume Lettre, PhD
Professor of Medicine, Université de Montréal and Montreal Heart Institute; Canada Research Chair in Genetics of Heart and Blood Diseases; Fellow of the College of the Royal Society of Canada
Olink Biomarker Summit – San Francisco | May 21, 2024
The Olink Biomarker Summit Series’ final stop is in San Francisco. Attendees will have the opportunity to network with other local biomarker researchers immersed in human disease studies. Key-opinion-leaders will be presenting their Olink data and taking questions from attendees.
Venue: AC Hotel by Marriott San Francisco Airport/Oyster Point Waterfront
Register for the San Francisco Summit
Agenda
11:30 a.m. | Registration, lunch & networking
12:30 p.m. | Welcome introduction – Tal Varsano, PhD, Business Development Manager, Olink Proteomics, Inc.
12:40 p.m. | Proteomic predictors of morbidity and mortality in treated HIV and asymptomatic CMV - Peter W. Hunt, MD, Professor of Medicine in the Division of Experimental Medicine (DEM) at the University of California San Francisco; Associate Chief for Research for the ZSFG-UCSF Department of Medicine
1:15 p.m. | Harnessing proteomics for enhanced understanding of myelin and axonal health - Ahmed Abdelhak, MD, HS Clinical Instructor, Division of Neuroinflammation and Glial Biology, Dept. of Neurology, University of California San Francisco
1:50 p.m. | Coffee break
2:10 p.m. | Circulatory prostate cancer proteome landscapes and prognostic biomarkers in metastatic castrate resistant prostate cancer - Manish Kohli MD, Professor, Division of Oncology, School of Medicine; Director, Physician Scientist Training Program, Department of Internal Medicine, Huntsman Cancer Institute, Salt Lake City, UT
2:45 p.m. | Rare variant influences on human plasma protein levels – Ryan Dhindsa, MD, PhD, Assistant Professor, Department of Pathology & Immunology, Baylor College of Medicine
3:20 p.m. | Multi-Omics Integration for the Design of Novel Therapies – Moderated by Cindy Lawley, PhD, Sr Director, Global Population Health, Olink Proteomics, Inc.
Panelist – Mark McCarthy, MD, Executive Director Human Genetics, Genentech; Tamar Uziel, PhD, Scientific Director Oncology, Abbvie; Sara Ahadi, PhD, Sr. Associate Director Multi-Omics, Alkahest/Grifols; Ryan Dhindsa, MD, PhD, Assistant Professor, Department of Pathology & Immunology, Baylor College of Medicine, Baylor College of Medicine; Ruchi Gupta, PhD, Head of Biomarker Development and Operations, Alector
3:50 p.m. | Closing remarks
4:00 p.m. | Happy hour
Meet some of our speakers
Peter Hunt, MD
Professor of Medicine in the Division of Experimental Medicine (DEM) at the University of California San Francisco; Associate Chief for Research for the ZSFG-UCSF Department of Medicine
Manish Kohli MD
Professor, Division of Oncology, School of Medicine; Director, Physician Scientist Training Program, Department of Internal Medicine, Huntsman Cancer Institute, Salt Lake City, UT
Ryan Dhindsa, MD, PhD
Assistant Professor, Department of Pathology & Immunology, Baylor College of Medicine
Ahmed Abdelhak, MD
HS Clinical Instructor, Division of Neuroinflammation and Glial Biology, Dept. of Neurology, University of California San Francisco
Event passed – Olink Biomarker Summit – Houston | April 2, 2024 | 11:30 AM – 5:00 PM CDT
The Olink Biomarker Summit Series is arriving in the beautiful city of Houston, Texas, offering you the opportunity to network with other biomarker researchers immersed in human disease studies. With presentations from key opinion leaders and local experts on site, this event promises to be a catalyst for insightful discussions and invaluable connections.
Venue: The Westin Houston Medical Center/Museum District
A celebratory happy hour for all attendees will begin at 5:00 PM CDT at the venue.
Agenda
11:30 a.m. | Check in and lunch served
12:00 p.m. | Introductions – Joe Albert, Director of Business Development- West, Olink Proteomics, Inc.
12:10 p.m. | Opening remarks: Proteomics: From discovery to clinical practice – Christie Ballantyne, MD, Professor, Department of Medicine; Chief, Section of Cardiovascular Research; Director, Center for Cardiometabolic Disease Prevention, Baylor College of Medicine
12:30 p.m. | Longitudinal proteomic exploration of subacute and chronic morbidity in children with congenital heart disease – Jesse Davidson, MD, MPH, MSc, Associate Professor, Pediatrics-Cardiology, University of Colorado
1:10 p.m. | Coffee and tea break
1:30 p.m. | Omics technologies in commercial spaceflight research – Harsha Doddapaneni, PhD, Associate Professor, Department of Molecular and Human Genetics, BCM Human Genome Sequencing Center (HGSC)
2:00 p.m. | The Octave MSDA test product journey: Improving insights for patients with MS utilizing a clinically validated assay developed on the Olink platform – Ferhan Qureshi, Vice President, Biomarker Product Development, Octave Bio
2:50 p.m. | Coffee and tea break
3:10 p.m. | Harnessing proteomics for diagnostic and prognostic insights in cancer research – Michael Förster, PhD, Scientific Director, Oncology & Rare Disease, Olink Proteomics, Inc.
4:00 p.m. | Multi-omics analysis reveals immune features associated with immunotherapy benefit in squamous cell lung cancer patients – Edwin Parra, MD, PhD, Associate Professor and Director of the Multiplex Immunofluorescence and Image Analysis Laboratory in the Department of Translational Molecular Pathology at The University of Texas MD Anderson Cancer Center
4:45 p.m. | Closing remarks
5:00 p.m. | Celebratory happy hour
Meet some of our speakers
Ferhan Qureshi
Vice President Biomarker Product Development, Octave Bioscience
Christie Ballantyne, MD
Professor, Department of Medicine; Chief, Section of Cardiovascular Research; Director, Center
for Cardiometabolic Disease Prevention, Baylor College of Medicine
Harsha Doddapaneni, PhD
Associate Professor, Department of Molecular and Human Genetics, BCM Human Genome Sequencing Center (HGSC)
Michael Förster, PhD
Scientific Director, Oncology & Rare Disease, Olink Proteomics, Inc.
Edwin Parra, MD, PhD
Associate Professor and Director of the Multiplex Immunofluorescence and Image Analysis Laboratory in the Department of Translational Molecular Pathology at The University of Texas MDAnderson Cancer Center
Jesse Davidson, MD, MPH, MSc
Associate Professor, Pediatrics-Cardiology, University of Colorado